View More View Less
  • 1 Centro de Desenvolvimento da Tecnologia Nuclear (CDTN)/Comissão Nacional de Energia Nuclear (CNEN), Av. Antônio Carlos 6627, Pampulha, Belo Horizonte, MG 31270-901, Brazil
  • | 2 Departamento de Biomedicina, Universidade Federal de Goiás, CAJ—Centro de Ciências Agrárias e Biológicas, BR 364, N. 3800—Setor Industrial, Jatai, GO 75801-615, Brazil
Restricted access

Abstract  

The proposal of this work was to investigate the effect of the radioactive (NH3)2PtCl2, cis-diamminedichloroplatinum (II) or CDDP* on malignant glioma cells and verify if the low-dose continuous internal radio-chemotherapy would be able to produce additive effects. The antitumoral activity of CDDP* and the non labeled cisplatin, CDDP, were evaluated in glioblastoma. Cisplatin was cytotoxic for glioblastoma cells in a dose dependent manner. Treatment with CDDP*, (IC50 = 1.75 ± 0.07 μM), proved to be more potent than using just CDDP, (IC50 = 4.96 ± 0.40 μM). These results suggest that cisplatin is a very potent radiosensitizer evoking a supra additive effect. Internal radio-chemotherapy treatment based on CDDP* may be useful alternative to reduce the drug concentration required for effective inhibition of glioblastoma growth.

Manuscript Submission: HERE

  • Impact Factor (2019): 1.137
  • Scimago Journal Rank (2019): 0.360
  • SJR Hirsch-Index (2019): 65
  • SJR Quartile Score (2019): Q3 Analytical Chemistry
  • SJR Quartile Score (2019): Q3 Health, Toxicology and Mutagenesis
  • SJR Quartile Score (2019): Q2 Nuclear Energy and Engineering
  • SJR Quartile Score (2019): Q3 Pollution
  • SJR Quartile Score (2019): Q3 Public Health, Environmental and Occupational Health
  • SJR Quartile Score (2019): Q3 Radiology, Nuclear Medicine and Imaging
  • SJR Quartile Score (2019): Q3 Spectroscopy
  • Impact Factor (2018): 1.186
  • Scimago Journal Rank (2018): 0.408
  • SJR Hirsch-Index (2018): 60
  • SJR Quartile Score (2018): Q2 Nuclear Energy and Engineering
  • SJR Quartile Score (2018): Q2 Pollution

For subscription options, please visit the website of Springer Nature.

Journal of Radionalytical and Nuclear Chemistry
Language English
Size A4
Year of
Foundation
1968
Volumes
per Year
4
Issues
per Year
12
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Springer Nature Switzerland AG
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0236-5731 (Print)
ISSN 1588-2780 (Online)